Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.720 -0.070 (-3.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 494,895
Open 1.790
Bid (Size) 1.720 (12)
Ask (Size) 1.730 (37)
Prev. Close 1.790
Today's Range 1.710 - 1.790
52wk Range 1.140 - 4.960
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
atai Life Sciences to Participate in Upcoming June Investor Conferences
From atai Life Sciences
Via GlobeNewswire
3 Penny Stocks to Make You the Millionaire Next Door
Explore the world of high-risk, high-reward top penny stocks to buy and uncover promising investment opportunities. 
Via InvestorPlace

Performance

YTD
-35.09%
-35.09%
1 Month
-13.13%
-13.13%
3 Month
+6.83%
+6.83%
6 Month
-51.27%
-51.27%
1 Year
-56.78%
-56.78%

More News

Read More
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Via Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
Via Benzinga
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in Upcoming May Investor Conference
From atai Life Sciences
Via GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
From atai Life Sciences
Via GlobeNewswire
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Invitae, CSX And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
Via The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Via Benzinga
Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations
Via Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
Via Benzinga
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From April 12, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 11, 2023
Via Benzinga
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
Via Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.